Atrial Fibrillation Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight's, "Atrial Fibrillation Pipeline Insight 2023" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the Atrial Fibrillation pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atrial Fibrillation pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Atrial Fibrillation Pipeline Report
• DelveInsight's Atrial Fibrillation pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Atrial Fibrillation treatment.
• The leading companies working in the Atrial Fibrillation Market include ARCA biopharma Inc., Anthos Therapeutics, Inc., Milestone Pharmaceuticals, Armaron Biosciences, Ono Pharmaceutical, Hanmi Pharmaceutical, HUYA Bioscience International, Hyloris Pharmaceuticals, Vivasc Therapeutics, Espero BioPharma, and others.
• Promising Atrial Fibrillation Pipeline Therapies in the various stages of development include Edoxaban, Rivaroxaban (Xarelto, BAY597939), Phenprocoumon (branded and generics), and others.
• July 2023: Bristol-Myers Squibb announced a study of Phase 4 clinical trials for Zio®XT Monitor. The purpose of this study is to determine if an AF detection intervention in men and women at least 70 years of age with undiagnosed atrial fibrillation (AF) or atrial flutter (AFL) reduces the person-years incidence rate of stroke compared to usual care (no AF detection intervention).
• October 2023: Janssen Research & Development Inc., announced a study of Phase 3 clinical trials for Milvexian and Apixaban. The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non- central nervous system (CNS) systemic embolism.

Request a sample and discover the recent advances in Atrial Fibrillation Treatment Drugs @ Atrial Fibrillation Pipeline Report- https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Atrial Fibrillation pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Atrial Fibrillation NDA approvals (if any), and product development activities comprising the technology, Atrial Fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Atrial Fibrillation Overview
Atrial fibrillation (also called Afib or AF) is an irregular heart rhythm (arrhythmia) that begins in the upper (atria) of your heart. In atrial fibrillation, the normal cycle of electrical impulses in the heart is interrupted. This leads to a fast, chaotic heart rhythm and poor movement of blood from your atria to lower chambers (ventricles).

Find out more about Atrial Fibrillation Therapeutics Assessment @ Atrial Fibrillation Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Atrial Fibrillation Emerging Drugs Profile
• Abelacimab: Anthos Therapeutics, Inc.
• Etripamil: Milestone Pharmaceuticals
• GENCARO: ARCA biopharma

Atrial Fibrillation Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the Atrial Fibrillation therapies. The Atrial Fibrillation companies which have their Atrial Fibrillation drug candidates in the most advanced stage, i.e. phase III include, Anthos Therapeutics, Inc.

Atrial Fibrillation Pipeline Segmentation
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Learn more about the emerging Atrial Fibrillation Pipeline Therapies @ Atrial Fibrillation Clinical Trials Assessment- https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Atrial Fibrillation Pipeline Report
• Coverage- Global
• Atrial Fibrillation Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Atrial Fibrillation Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Atrial Fibrillation Companies- ARCA biopharma Inc., Anthos Therapeutics, Inc., Milestone Pharmaceuticals, Armaron Biosciences, Ono Pharmaceutical, Hanmi Pharmaceutical, HUYA Bioscience International, Hyloris Pharmaceuticals, Vivasc Therapeutics, Espero BioPharma, and others.
• Atrial Fibrillation Pipeline Therapies- Edoxaban, Rivaroxaban (Xarelto, BAY597939), Phenprocoumon (branded and generics), and others.

Dive deep into rich insights for new drugs for Atrial Fibrillation Treatment, Visit @ Atrial Fibrillation Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Atrial Fibrillation: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Atrial Fibrillation- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Abelacimab: Anthos Therapeutics, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. NP 202: Armaron Biosciences
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Hip-2001: Hanmi Pharmaceutical
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Atrial Fibrillation Key Companies
21. Atrial Fibrillation Key Products
22. Atrial Fibrillation- Unmet Needs
23. Atrial Fibrillation- Market Drivers and Barriers
24. Atrial Fibrillation- Future Perspectives and Conclusion
25. Atrial Fibrillation Analyst Views
26. Atrial Fibrillation Key Companies
27. Appendix

For further information on the Atrial Fibrillation Pipeline therapeutics, reach out to Atrial Fibrillation Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.